Abstract
F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78% CEA-seropositive and in 64% seronegative patients. the fraction of documented lesions which was imaged was 69% in CEA-seropositive patients and 39% in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80%. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.
| Original language | English |
|---|---|
| Pages (from-to) | 577-589 |
| Number of pages | 13 |
| Journal | Nuclear Medicine Communications |
| Volume | 9 |
| Issue number | 8 |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Radiological and Ultrasound Technology
Cite this
Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5. / Riva, P.; Paganelli, G.; Callegaro, L.; Bartoli, M. G.; Turci, D.; Benini, S.; Deleide, G.; Scassellati, G. A.; Viale, G.; Siccardi, A. G.
In: Nuclear Medicine Communications, Vol. 9, No. 8, 1988, p. 577-589.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5
AU - Riva, P.
AU - Paganelli, G.
AU - Callegaro, L.
AU - Bartoli, M. G.
AU - Turci, D.
AU - Benini, S.
AU - Deleide, G.
AU - Scassellati, G. A.
AU - Viale, G.
AU - Siccardi, A. G.
PY - 1988
Y1 - 1988
N2 - F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78% CEA-seropositive and in 64% seronegative patients. the fraction of documented lesions which was imaged was 69% in CEA-seropositive patients and 39% in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80%. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.
AB - F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78% CEA-seropositive and in 64% seronegative patients. the fraction of documented lesions which was imaged was 69% in CEA-seropositive patients and 39% in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80%. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.
UR - http://www.scopus.com/inward/record.url?scp=0023706136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023706136&partnerID=8YFLogxK
M3 - Article
C2 - 3173916
AN - SCOPUS:0023706136
VL - 9
SP - 577
EP - 589
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
SN - 0143-3636
IS - 8
ER -